Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

10.2174/187152512800388948

10.1517/14656566.2010.495119

10.2337/dc14-S014

10.1185/03007990902801147

[AFSSAPS] Agence française de sécurité sanitaire des produits de santé. Use of medications containing pioglitazone (Actos®, Competact®) Suspended. 2011. [accessed 24 Feb 2012]. www.afssaps.fr/content/download/34175/447382/version/1/file/Press-release-Suspension-Pioglitazone.pdf.

10.1152/ajprenal.00289.2005

10.2174/138955712798995048

10.1038/nm.3159

10.1053/j.gastro.2008.06.047

10.3132/dvdr.2006.023

10.1517/14740338.7.4.367

10.2337/diacare.23.8.1067

10.1016/j.jdiacomp.2014.05.007

10.1016/j.mehy.2014.01.022

10.1016/j.critrevonc.2007.07.004

10.7326/0003-4819-132-2-200001180-00006

American Heart Association.Cardiovascular disease & diabetes. 2012. [accessed 2014 Dec 28]. http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp#.

10.1016/j.jdiacomp.2007.06.004

10.1185/030079907X242494

10.1002/hep.22828

10.2337/diacare.23.11.1605

Associated Press. 2010. Keep Avandia on market: FDA panel. CBC News. July 14. [accessed 2010 Jul 20]. http://www.cbc.ca/health/story/2010/07/14/avandia-heart-fda.html.

10.1111/j.1463-1326.2010.01225.x

10.1016/S0140-6736(05)74382-8

10.1016/S0140-6736(05)76277-2

10.2217/fca.10.86

Azoulay L, 2009, Pharmacoepidemiol Drug Saf, 19, 343, 10.1002/pds.1883

10.1136/bmj.e3645

10.1161/CIRCULATIONAHA.112.000678

10.1111/j.1463-1326.2005.00497.x

10.4103/2230-8210.131223

10.1073/pnas.012610299

10.1016/j.bbr.2014.08.014

10.1016/S0002-9629(15)40570-1

10.1172/JCI27955

10.1001/jama.1992.03490230063029

10.2337/diacare.19.12.1388

10.1159/000106830

10.2337/diacare.29.03.06.dc05-2004

10.7326/0003-4819-152-4-201002160-02013

Bazelier MT, 2013, Front Endocrinol (Lausanne), 4, 11

10.2174/15748863113086660069

10.1007/s00223-012-9591-8

10.1016/j.trsl.2012.08.006

10.1016/j.diabres.2005.02.011

10.1111/j.1742-1241.2004.00291.x

10.1056/NEJMoa060326

10.2337/diacare.23.1.128

10.1155/2013/628628

Benbow A, 2001, BMJ, 322, 236, 10.1136/bmj.322.7280.236

10.1007/BF03350807

Benvenuti S, 2012, J Endocrinol Invest, 35, 365

10.1210/jc.2007-0431

10.1111/j.1365-2265.2010.03784.x

10.1001/jamainternmed.2014.5294

10.1016/j.diabres.2006.09.010

10.1038/sj.clpt.6100146

10.1007/s00125-005-0034-1

10.1111/j.1464-5491.2010.03187.x

10.1046/j.0022-202X.2003.22111.x

10.1210/jc.2012-4018

10.1210/jc.2009-2638

10.1002/pds.1954

10.1517/13543784.17.10.1465

Blanquicett C, 2008, Cancer Ther, 6, 25

10.2337/dc07-zb09

10.2337/db06-0481

10.2165/00002018-200932070-00001

10.1016/S0006-2952(01)00817-6

10.1007/BF03347060

10.1530/eje.0.1500863

10.1210/jc.2006-0614

10.1210/jc.2012-4096

10.1023/A:1015895925374

Booth AM, 2000, Am J Gastroenterol, 95, 557, 10.1016/S0002-9270(99)00865-5

10.1042/BST0341341

10.1007/s10552-010-9697-0

Borges JL, 2011, Diabetes Obes Metab, 13, 1036, 10.1111/j.1463-1326.2011.01461.x

10.1517/14740338.2013.741585

10.1634/theoncologist.2012-0302

10.1080/01635581.2012.676141

10.1345/aph.1Q400

10.1056/NEJMc071602

10.1111/dom.12099

10.1007/s00592-005-0183-1

Broulík PD, 2011, Folia Biol (Praha), 57, 133

10.1016/j.genm.2008.07.006

Bruedigam C, 2010, Stem Cells, 28, 916, 10.1002/stem.405

10.2337/diabetes.51.9.2796

10.1023/A:1024038127156

10.2337/dc12-0002

10.1016/j.ejcb.2010.04.002

10.1038/oby.2002.137

10.1016/j.tem.2012.03.001

10.1016/j.neuroscience.2011.07.046

Carta AR, 2011, Parkinsons Dis, 2011, 689181

10.1097/MJT.0b013e31817534d5

Centers for Disease Control and Prevention, 2014, National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014

10.1007/s12020-010-9426-1

10.1111/j.1572-0241.2005.41690.x

10.1016/j.bone.2006.07.029

10.1038/nature07413

10.1002/hep.25509

10.1016/j.ajpath.2013.10.020

10.1345/aph.1K013

Chao T-K, 2016, Neurotoxicology, 0161, 30016

10.1007/s00125-004-1651-9

10.1210/endo.135.2.8033830

10.1016/j.bbaexp.2006.01.005

10.1016/j.yexcr.2015.09.005

10.1016/j.nbd.2011.08.016

10.1007/s000110050622

10.1001/archinte.164.19.2097

10.1111/jnc.12264

10.1007/s10059-012-2240-z

10.1159/000086748

10.1111/j.1463-1326.2012.01631.x

10.1007/s001980050232

10.1016/j.metabol.2013.07.004

10.4049/jimmunol.164.3.1364

10.1016/S0140-6736(07)61488-3

10.1002/pds.1048

10.1002/pds.1615

10.1080/00365590050509869

10.1093/toxsci/kfi266

10.1111/dom.12308

10.1517/13543784.2013.839659

10.1016/j.bcp.2006.01.002

10.1007/s00125-012-2668-0

10.1503/cmaj.112102

10.1177/14746514060060030601

10.1093/aje/kwv109

10.1191/0961203305lu2223oa

10.1146/annurev.pharmtox.40.1.491

10.1016/S0027-5107(99)00232-8

10.1111/dom.12109

10.1042/bj20021812

10.3233/JAD-2006-9209

10.1007/s00198-005-1909-1

10.1634/theoncologist.2013-0087

10.1074/jbc.274.45.32048

10.1677/joe.0.1690453

10.1111/j.1600-0625.2006.00402.x

10.1016/j.bbagen.2013.10.021

10.1007/s00125-004-1560-y

10.1507/endocrj.52.299

10.1016/j.clinthera.2005.09.003

10.1111/j.1365-2710.2006.00756.x

Desai A, 2007, Gibaldi's drug delivery systems in pharmaceutical care

10.1016/0278-6915(95)00039-5

10.1038/384039a0

10.7326/0003-4819-147-8-200710160-00182

Diamond GA, 2007, N Engl J Med, 357, 938

10.1002/cmdc.201100598

10.1185/03007990902973300

10.1080/01926230601072327

10.1592/phco.29.7.775

10.2165/00002018-200932030-00002

10.1016/j.atherosclerosis.2008.03.002

10.1016/S0140-6736(05)67528-9

10.1001/archinternmed.2009.214

10.1371/journal.pone.0006080

10.1371/journal.pmed.1000154

10.2337/db06-0391

10.1185/03007995.2012.681636

10.1007/s001250051508

10.1210/jcem-65-3-499

10.1210/edrv.18.6.0318

10.1080/13547500500218682

Ehrmann DA, 1997, J Clin Endocrinol Metab, 82, 2108

El Hage J, Orloff D. 2005. Rodent carcinogenicity findings associated with PPAR agonists and their regulatory recommendations. Paper presented at: 3rd International Symposium on PPARS Efficacy and Safety; Monte Carlo, Monaco.

El Hage. 2005. Toxicity profiles of peroxisome proliferator-activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar. US FDA Endocrinologic and Metabolic Drugs Advisory Committee. [accessed 2014 Jul 26]. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4169S2_02_02-FDA-ElHage.ppt.

[EMA] European Medicines Agency. 2011a. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. [accessed 2011 Dec 12]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf.

[EMA] European Medicines Agency. 2011b. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact. [accessed 2011 Dec 12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf.

10.2337/dc07-0717

10.1016/j.jacc.2006.12.048

Erdmann E, 2007, Vasc Health Risk Manag, 3, 355

10.1111/dom.12608

10.1111/dom.12180

10.1111/j.1753-0407.2010.00082.x

10.1055/s-0034-1370989

10.1038/nm1025

10.1002/pds.652

10.1007/s40264-013-0086-y

10.1074/jbc.272.30.18779

10.1016/S0014-5793(98)01273-3

10.1016/j.metabol.2016.01.012

10.1111/dme.12144

10.2337/diabetes.55.04.06.db05-1100

10.2217/cer.13.87

10.1002/pds.1804

10.1001/jama.283.13.1695

10.1016/j.amjmed.2003.09.005

Forbes. 2013. The hidden agenda behind the FDA's new Avandia hearings. [accessed 2013 May 30]. http://www.forbes.com/sites/matthewherper/2013/05/23/steven-nissen-the-hidden-agenda-behind-the-fdas-avandia-hearings/.

10.7326/0003-4819-132-2-200001180-00005

10.1007/s001250051248

10.1016/j.diabres.2012.11.013

10.2337/diab.32.9.804

10.1016/S0046-8177(00)80229-4

10.1016/S0140-6736(00)04960-6

10.1097/01.med.0000433065.16918.83

10.1097/SHK.0b013e318225b29a

10.1080/09513590500430575

10.1016/j.atherosclerosis.2006.06.026

10.1007/s00198-005-1877-5

10.1002/pds.1470

10.1016/S0140-6736(06)69420-8

10.1038/ncpendmet0640

10.18433/J3TG6H

10.1016/8756-3282(88)90024-5

10.1111/j.1751-7133.2010.00154.x

10.1016/j.cardfail.2008.02.007

Gimble JM, 1996, Mol Pharmacol, 50, 1087

10.2337/dc10-0666

10.7326/0003-4819-129-1-199807010-00008

Giustina A, 2000, J Clin Endocrinol Metab, 85, 526

10.1210/jc.2007-2249

10.2337/diacare.28.7.1547

10.4158/EP15748.DSC

Gorter KJ, 2012, BMJ Clin Evid, 2012, 0609

Gradišer M, 2007, Croat Med J, 48, 87

10.1001/jama.286.7.831

10.1016/S0002-9343(02)01529-2

Graham DJ, Green L. 1999. The epidemiology of troglitazone hepatotoxicity. FDA Metabolic-Endocrine Drugs Advisory Committee Meeting; March 26; Bethesda, Maryland. [accessed 2014 Aug 2]. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3499t1a.pdf.

10.1001/jama.2010.920

10.1152/physrev.1998.78.3.783

10.1016/0168-8227(94)90126-0

10.1530/EJE-13-0793

10.1210/jc.2006-2646

10.1111/j.1463-1326.2008.00931.x

10.1007/s11060-010-0185-x

10.1016/j.clinthera.2009.01.004

10.2165/00019053-200220001-00001

10.1517/13543784.6.8.1025

10.1007/s00223-010-9352-5

10.1186/1475-2891-13-17

[GSK] Glaxo Smith Kline. 2012.PrAvandia®rosiglitazone (as rosiglitazone maleate). Product Monograph. [accessed 2016 Sep 20]. http://ca.gsk.com/media/522034/avandia.pdf.

[GSK] Glaxo Smith Kline. Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia®(rosiglitazone maleate) tablets for type 2 diabetes mellitus. Dear Healthcare Provider Letter. 2007b. [accessed 2015 Mar 25]. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153903.pdf.

[GSK] Glaxo Smith Kline. Study no. ZM2005/00181/01: Avandia cardiovascular event modeling project. 2007a. [accessed 2015 Aug 30]. http://www.gsk-clinicalstudyregister.com/study/ZM2005/00181/01?study_ids=ZM2005/00181/01#rs.

10.1038/nm780

10.1038/nm1278

10.1038/sj.neo.7900050

10.1002/ana.21573

10.1016/j.jocd.2008.09.003

10.4103/2230-8210.163187

10.1210/jc.2009-1385

10.1002/pds.1722

10.1530/eje.1.01853

10.4103/0256-4947.51739

10.1161/01.CIR.0000025403.20953.23

10.1016/j.diabet.2012.03.002

10.2337/dc13-2289

Hampton T., 2007, JAMA, 297, 1645

10.2337/diacare.27.1.141

10.1016/j.numecd.2005.12.003

10.1186/1475-2840-10-65

10.1111/j.1532-5415.2009.02067.x

10.2174/156720511796391935

10.1210/jc.2010-2077

10.1592/phco.2005.25.10.1329

10.1159/000120028

10.1002/dmrr.249

10.1007/s13277-013-1278-x

10.1073/pnas.2536828100

10.1093/annonc/mdr534

10.1172/JCI200316575

10.2174/157015911798376325

10.1016/j.ejphar.2009.06.051

10.1002/dmrr.1187

10.7326/0003-4819-130-2-199901190-00021

10.1016/j.neuro.2017.03.006

10.1161/01.ATV.0000176192.16951.9a

10.1007/s00228-012-1299-1

Hisatake JI, 2000, Cancer Res, 60, 5494

10.1016/j.amjmed.2003.09.018

10.2337/dc11-s233

10.1016/S0140-6736(09)60953-3

10.1007/s00125-005-1869-1

10.1056/NEJMoa073394

10.1016/j.amjhyper.2005.05.035

10.2337/diacare.21.9.1462

10.1016/j.metabol.2008.02.009

10.1172/JCI117936

10.1126/science.7678183

10.1016/j.bone.2007.11.016

10.1007/s40264-013-0080-4

10.2165/00002018-200932080-00006

10.1007/s00125-009-1609-z

10.1111/j.1471-4159.2008.05626.x

10.1016/j.lfs.2007.11.033

10.1007/s10059-011-0026-6

[IARC] International Agency for Research on Cancer and [WHO] World Health Organization. 2012. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. [accessed 2015 Sep 23]. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

10.1111/j.1365-2036.2008.03723.x

Indiana University. 2016. Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease (PIOPKD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). https://www.clinicaltrials.gov/ct2/show/study/NCT02697617. Identifier: NCT02697617.

10.1001/jama.294.3.334

International Diabetes Federation. 2014. About diabetes. Risk factors. [accessed 2014 Dec 27]. http://www.idf.org/about-diabetes/risk-factors.

10.1007/s00125-012-2534-0

10.2337/dc14-2441

10.1007/BF02742962

10.1007/s005920050142

10.1016/0026-0495(85)90101-5

10.1517/14740338.2.6.581

10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M

10.2337/diacare.22.8.1382

10.7326/0003-4819-132-8-200004180-00021

10.2337/dc06-0440

10.1093/aje/kwm106

10.1074/jbc.M109.040741

Jenner RK. 2000. Rezulin: fast track to failure. Trial. American Association for Justice. [accessed 2014 Jul 31]. http://www.highbeam.com/doc/1G1-63795755.html.

10.2337/diabetes.51.7.2170

10.3346/jkms.2014.29.2.238

10.1007/s00125-010-1933-3

10.1016/0026-0495(85)90192-1

Jones JI, 1995, Endocr Rev, 16, 3

10.1007/s00592-014-0691-y

10.1111/j.1432-1033.1995.219_1.x

Jones SG, 2009, Am J Manag Care, 15, 491

10.1136/bmj.b2942

10.1001/jama.2010.954

10.1056/NEJMoa066224

10.2337/db10-1392

10.2337/dc07-2270

10.1016/j.jneuroim.2009.04.011

10.1185/03007990903328124

10.1185/03007990902820816

10.1007/s00774-010-0160-9

10.1152/ajpendo.00388.2009

10.1136/hrt.2008.162842

10.1111/1753-0407.12301

10.1016/0002-9149(74)90089-7

10.1016/j.arcmed.2002.07.001

10.2741/2802

10.2165/00002018-200730090-00002

10.1016/j.beem.2013.02.002

10.2165/00002018-200831100-00003

10.1056/NEJM199001113220206

10.1046/j.1365-2265.2001.01214.x

10.1016/j.ghir.2005.06.007

10.1016/j.jacc.2010.02.014

10.1007/s11883-008-0062-7

10.1152/ajpendo.00128.2004

10.1093/aje/155.10.926

10.1016/j.jad.2011.06.033

10.1007/s40263-014-0158-2

10.4065/78.9.1088

10.1172/JCI117899

10.1056/NEJMoa1506930

10.1111/j.1559-4564.2006.05675.x

10.1111/j.1365-2265.2012.04411.x

10.4093/dmj.2012.36.6.460

10.1152/ajpendo.00440.2004

Kirk JK, 1999, J Fam Pract, 48, 879

10.1210/rp.56.1.239

10.1038/nrclinonc.2016.120

10.1345/aph.1R754

10.1111/j.1572-0241.2000.01707.x

10.1093/eurheartj/ehp604

10.1111/j.1463-1326.2011.01411.x

10.1136/bmj.i3903

10.1002/pds.1640

10.1111/j.1464-410X.2006.06268.x

10.1111/j.1464-410X.2007.07070.x

Krieter PA, 1994, Drug Metab Dispos, 22, 625

10.1002/jbmr.1918

10.1016/j.kjms.2013.09.011

10.1073/pnas.95.26.15592

10.1093/carcin/bgs314

10.1016/j.expneurol.2006.04.006

10.1016/j.ejphar.2008.08.004

10.1007/s00125-006-0468-0

LaSalle JR, 2006, Am J Manag Care, 12, S369

10.1210/en.2006-1587

10.1016/j.bone.2005.07.008

10.2337/diacare.25.5.815

10.1210/en.2006-1121

10.2337/diabetes.53.suppl_3.S67

10.1126/science.1087344

10.3349/ymj.2013.54.6.1313

10.1007/s11064-006-9138-3

10.1371/journal.pone.0085479

10.1023/A:1015332726303

10.1074/jbc.272.6.3406

10.1074/jbc.270.22.12953

10.1016/j.cell.2005.11.026

10.1016/S8756-3282(03)00237-0

10.2337/dc10-1068

10.1002/pds.3619

10.1001/jama.2015.7996

10.1007/s00774-009-0104-4

10.1016/S1056-8727(00)00076-3

10.4093/dmj.2013.37.1.81

10.1111/j.1365-2265.2010.03917.x

10.1016/j.bone.2007.06.017

10.1001/jama.2014.3321

10.1001/jama.298.10.1180

10.1001/jama.298.22.2634

10.1007/s00223-012-9623-4

10.1016/j.bone.2012.09.038

10.1503/cmaj.080486

10.1177/0192623307311757

10.1002/ijc.23765

Lubet RA, 2004, Proc Am Assoc Cancer Res, 45, 725

10.1016/j.steroids.2009.10.012

10.1016/S1701-2163(16)32915-2

Lumpkin MM. 2000. Troglitazone: presentation to the Endocrinologic and Metabolic Drugs Advisory Committee; May 19. Bethesda (MD): US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/00/slides/3615s1a/sld001.htm.

10.1007/s001980170069

10.1007/s10654-012-9674-x

10.1111/j.1464-5491.2010.03048.x

10.1016/j.lfs.2013.10.022

10.1002/cncr.25641

10.7326/0003-4819-135-4-200108210-00029

10.1016/j.ahj.2013.05.004

10.1007/s00198-004-1786-z

10.1023/A:1005450519498

10.1093/jnci/djs328

10.1016/j.bone.2009.06.006

Mannucci E, 2007, N Engl J Med, 357, 938

10.1345/aph.1E072

10.1002/pds.1630

10.3233/JRS-120581

Martino R, 2016, Neurotoxicology, 0161, 30049-3

10.1161/CIRCULATIONAHA.105.535484

10.12659/MSM.430336

10.1002/dmrr.478

10.7326/0003-4819-136-6-200203190-00008

10.1186/1471-2407-12-410

McIntosh B, 2012, Open Med, 6, e62

McKay KA, 2016, Neurotoxicology, 0161, 30042-0

Meema H, 1967, Can Med Assoc J, 96, 132

10.1001/archinte.168.8.820

10.1210/jc.2008-0639

10.1016/j.taap.2012.06.014

Misbin RI. 1998. Review of liver toxicity of troglitazone. Meeting of the Food and Drug Administration Cardiorenal Advisory Committee; January 21. Bethesda (MD): US Food and Drug Administration.

10.1016/S0140-6736(05)64289-4

10.1001/jama.2013.8141

10.1007/978-0-387-69737-6

10.1002/art.25061

10.1007/s00592-013-0504-8

10.1016/S0955-0674(98)80015-X

10.2165/11596510-000000000-00000

10.1073/pnas.180329197

10.1023/A:1005405526283

Nafrialdi, 2012, Acta Acta Med Indones, 44, 28

10.2174/1874467211205020292

10.1016/S0168-8227(01)00319-9

10.1016/S0002-9440(10)61730-0

10.2337/diacare.27.6.1349

10.1210/jcem-68-6-1027

10.1056/NEJM199608293350902

10.1161/01.CIR.0000103683.99399.7E

10.2337/diacare.27.1.256

10.1007/s00125-012-2538-9

10.1007/s00125-012-2769-9

10.1002/hep.1840380427

10.7326/0003-4819-129-1-199807010-00009

New York Times. 2013. F.D.A. Lifts Some Restrictions on Avandia. [accessed 2013 Nov 25]. http://www.nytimes.com/2013/11/26/business/fda-lifts-some-restrictions-on-avandia.html?_r=0.

10.2337/diacare.24.7.1192

10.1007/s00592-010-0187-3

10.1016/S1474-4422(15)00144-1

10.1002/bdrb.21052

10.1001/jama.299.13.1561

10.1001/jama.294.20.joc50147

10.1056/NEJMoa072761

Nissen SE, 2007, N Engl J Med, 357, 939

10.1016/S0092-8674(00)80726-6

10.1507/endocrj.46.795

10.1210/endo.140.11.7116

10.1172/JCI1235

10.1155/2008/103167

10.1007/s11481-011-9282-7

10.3109/10641963.2010.531845

Oz S, 2006, J Natl Med Assoc, 98, 1598

10.1111/j.1540-8175.2009.01083.x

10.1007/s00592-008-0090-3

10.2337/db05-1183

10.1038/nature03988

10.1046/j.1463-1326.1999.00020.x

10.1002/cbf.3025

10.1016/j.expneurol.2006.01.018

10.1185/03007990903350011

10.1007/s00125-012-2767-y

10.1016/S1056-8727(03)00072-2

10.1007/s11892-005-0091-3

10.1111/j.1540-9740.2005.04434.x

10.1007/s40495-015-0026-x

10.1359/jbmr.090725

10.2337/diacare.24.2.308

10.2337/dc10-2412

10.1038/sj.bjp.0702158

10.7326/0003-4819-137-10-200211190-00023

10.2337/diacare.27.2.484

10.1038/nrc2536

10.1016/j.semcdb.2012.01.003

10.7326/0003-4819-133-9-200011070-00034

Prigeon RL, 1998, J Clin Endocrinol Metab, 83, 819

10.1002/hep.20012

10.1056/NEJMe078099

10.1056/NEJMe078116

10.2337/diacare.24.7.1226

10.1016/j.jhep.2010.04.008

10.1053/j.gastro.2008.03.078

10.4049/jimmunol.177.8.5068

10.1111/jgs.12722

10.1152/physrev.1995.75.3.473

10.1007/s11936-001-0094-6

Reaven GM., 2005, Panminerva Med, 47, 201

10.1074/jbc.273.49.32679

10.1016/j.bone.2006.03.003

10.1359/jbmr.051105

10.1016/S0140-6736(10)60706-4

10.1073/pnas.95.13.7614

10.1016/j.expneurol.2012.08.012

10.1016/j.bmc.2011.12.008

10.3109/00365519509089621

10.1038/sj.tpj.6500369

10.1038/nsmb.2054

10.1111/j.1464-5491.2005.01610.x

10.1185/03007991003733239

10.1186/1475-2840-10-18

10.1111/j.1368-5031.2005.00652.x

10.1530/ERC-12-0203

10.1097/00019501-200108000-00011

Rosenstock J, 2002, Int J Clin Pract, 56, 251, 10.1111/j.1742-1241.2002.tb11251.x

10.1016/j.ijcard.2012.04.019

10.1210/en.2011-1689

10.1210/en.2003-0746

10.1161/01.CIR.94.11.2837

10.1016/j.dsx.2013.10.020

10.1016/j.toxlet.2009.10.014

10.14712/18059694.2019.101

10.1006/bbrc.2000.3868

10.2337/diab.45.12.1661

10.1056/NEJMoa0907929

10.1016/S1542-3565(04)00457-4

10.2337/db10-1672

10.1016/j.neurobiolaging.2009.10.009

10.1038/sj.onc.1205279

Saul S. 2007. Heart attack risk seen in drug for diabetes. New York Times. May 22. [accessed 2010 Dec 3]. Available from:http://www.nytimes.com/2007/05/22/business/22drug.html.

10.1111/j.1464-5491.2009.02857.x

10.1111/j.1464-5491.2009.02816.x

Scheen AJ., 2001, Diabetes Metab, 27, 305

10.1210/jc.2003-030861

10.1023/A:1005510132625

10.1189/jlb.0803402

10.1002/j.1460-2075.1996.tb00918.x

Schulte PA, 1987, Occup Med, 2, 85

10.1210/en.2005-0601

10.1210/jcem.86.1.7139

10.1210/jc.2005-2226

10.1007/s11892-004-0039-z

10.1007/s00223-013-9703-0

10.3233/JAD-2012-111661

10.1111/cas.12411

10.1007/s005920300014

10.1053/S1542-3565(03)00198-8

10.1007/s00774-008-0023-9

10.1210/jc.2006-1268

Shaya FT, 2009, P T, 34, 490

10.2337/diacare.21.12.2140

10.1111/j.1365-2265.2006.02614.x

10.1016/j.neulet.2010.01.046

10.1001/jama.298.10.1189

10.1210/jc.2004-0705

10.1210/jc.2008-2157

10.1172/JCI30335

10.4093/dmj.2012.36.5.371

10.1677/joe.1.05723

10.1016/1056-8727(95)00062-3

10.1007/s00223-004-0224-8

10.1016/j.mayocp.2015.06.013

10.2337/diabetes.47.4.507

10.1038/31701

10.1111/j.1463-1326.2008.00991.x

10.1001/jama.2011.939

10.1016/j.ahj.2006.11.005

10.1002/pds.1700

Stolberg SG. 1999. Stricter rules are urged on use of a diabetic drug. New York Times. Mar 27. Sect. A:9.

10.1001/archinte.165.14.1612

10.1359/JBMR.040311

10.2337/diacare.25.10.1691

10.1186/1472-6823-11-11

10.1185/03007995.2011.595001

10.1016/j.neuint.2006.03.020

10.1016/S0168-8227(00)00119-4

10.1093/toxsci/kfp256

10.1186/1472-6823-9-10

10.1182/blood-2007-06-096222

10.1016/j.bbalip.2007.02.005

Takeda Pharmaceuticals North America Inc. 2007. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS®(pioglitazone HCl) tablets for type 2 diabetes mellitus. Letter to healthcare providers. Deerfield (IL).

Takeda Pharmaceuticals U.S.A. Inc. 2009. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. [accessed 2010 Aug 26]. http://www.actos.com/actospro/home.aspx.

10.1016/j.diabres.2008.07.008

10.1186/1752-1947-5-200

10.1111/j.1464-5491.2004.01258.x

10.1093/toxsci/kfm083

10.1002/pds.3360

10.1016/j.cell.2005.02.008

10.1016/S1089-3261(03)00020-5

10.2165/11316510-000000000-00000

10.1128/MCB.15.1.351

10.1101/gad.8.10.1224

10.1016/0092-8674(94)90006-X

10.1016/0959-437X(95)80025-5

10.1146/annurev.biochem.77.061307.091829

10.1111/ene.12883

10.1007/s002230020018

10.1016/j.urology.2014.02.074

10.1503/cmaj.1090003

10.1185/03007991003715079

10.1080/10590501.2012.735519

10.1007/s00125-011-2171-z

10.2337/dc11-1449

10.1016/j.canep.2013.03.013

Tsirella E, 2012, J Physiol Pharmacol, 63, 201

10.1006/bbrc.2000.2436

10.1136/bmj.i1541

10.2337/diacare.22.7.1196

Turner HE., 2001, Handbook of acromegaly

10.1016/j.cardiores.2007.06.003

10.3233/JAD-2010-100939

10.1136/bmj.b4731

Unnikrishnan R, 2012, J Assoc Physicians India, 60, 66

10.1038/sj.bjp.0702245

[US FDA] United States Food and Drug Administration. 1997. Patient testing and labeling strengthened for Rezulin. FDA Talk Paper: T97-61. Rockville (MD): US Food and Drug Administration.

[US FDA] United States Food and Drug Administration. 1999. Actos label information. [accessed 2014 Jul 23]. http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21073lbl.pdf.

[US FDA] United States Food and Drug Administration. 2005. Muraglitazar Briefing Document, Safety Endocrine and Metabolic Drugs Advisory Committee Meeting; September 9. [accessed 2016 Sep 21]. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169b2_02_03-fda-medoff-safety.pdf.

[US FDA] United States Food and Drug Administration. 2010a. FDA significantly restricts access to the diabetes drug Avandia. FDA News Release. [accessed 2010 Sep 23]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm226975.htm.

[US FDA] United States Food and Drug Administration. 2010b. FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. September. [accessed 2010 Oct 3]. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.

[US FDA] United States Food and Drug Administration. 2011a. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. [accessed 2011 Dec 21]. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm.

[US FDA] United States Food and Drug Administration. 2011b. Drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. [accessed 2011 Sep 3]. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm.

[US FDA] United States Food and Drug Administration. 2013a. Summary minutes of the joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee; June 5–6. [accessed 2013 Nov 25]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM369180.pdf.

[US FDA] United States Food and Drug Administration. 2013b. FDA requires removal of certain restrictions on the diabetes drug Avandia. FDA News Release. [accessed 2013 Nov 25]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm.

[US FDA] United States Food and Drug Administration. 2013c. FFDA approves three new drug treatments for type 2 diabetes. FDA News Release. [accessed 2016 Sep 21]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm336942.htm.

[US FDA] United States Food and Drug Administration. 2016. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. [accessed 2017 Jan 28]. http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm.

10.1007/s40261-013-0106-9

10.1681/ASN.2008040415

10.7326/0003-4819-122-6-199503150-00002

10.1530/EJE-11-1061

10.1016/j.etp.2008.04.009

10.1242/jcs.01042

10.7326/0003-4819-129-12-199812150-00032

10.1007/s00125-005-1786-3

10.1007/s00198-006-0253-4

10.1038/nrendo.2009.219

10.1210/jc.2005-1073

10.2337/diabetes.52.2.283

10.1007/s12307-014-0161-7

10.1016/j.cytogfr.2009.05.007

10.1016/8756-3282(93)90252-6

10.1002/pds.1598

10.1007/s00774-012-0374-0

10.1038/aps.2011.81

10.1074/jbc.M203436200

Wass JA, 2002, Oxford textbook of endocrinology, 1

10.1056/NEJM199803263381314

Watson GS, 2005, Am J Geriatr Psychiatry, 13, 950

10.1111/j.1365-2125.2012.04325.x

10.1155/2011/867180

10.1002/jbmr.5650040114

10.1210/en.2003-1580

10.1210/en.2012-1243

10.1074/jbc.272.32.20230

10.1172/JCI7231

10.1155/2008/527048

10.1161/01.STR.0000257974.06317.49

10.1146/annurev.biochem.70.1.341

10.1001/archinte.168.21.2368

10.1136/bmj.315.7122.1559n

10.4049/jimmunol.178.7.4129

10.1007/s12020-012-9826-5

10.1016/j.arcmed.2006.10.003

10.1158/1535-7163.MCT-05-0528

10.1111/j.1464-5491.2005.01656.x

10.1097/SHK.0b013e3181cc0738

10.1155/2008/943614

10.2337/dc11-0627

10.2337/dc06-2606

10.1007/s11892-013-0378-8

10.1177/1474651411402630

10.1158/1078-0432.CCR-06-1947

10.1056/NEJMra041001

10.1002/ijc.10980

Young PW, 1998, J Pharmacol Exp Ther, 284, 751

10.2337/diabetes.48.12.2414

10.1016/j.bbalip.2007.04.021

10.1002/da.22340

10.1073/pnas.0501744102

10.1073/pnas.0403652101

10.1152/ajpendo.00664.2006

10.1210/jc.2013-4182

10.1182/blood-2004-02-0664

10.1371/journal.pone.0102706

10.1016/S0006-291X(02)00138-9

10.1016/j.diabres.2010.09.013

10.1016/j.diabres.2012.05.006

10.1016/j.bone.2014.08.010

10.1210/jc.2009-0572

10.1016/j.clinthera.2014.06.035

10.1016/j.clinthera.2009.11.003